相关实验视频
Updated: Jan 12, 2026

Comprehensive Analysis of Drug Response using the FLICK Assay
Published on: June 6, 2025
探索glofitamab的不良事件概况:使用FDA不良事件报告系统进行不成比例分析
Meng Zhou1, Cheng Jiang1,2,3, Chuanyong Su1
1Zhejiang Academy of Traditional Chinese Medicine, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang, China.
这项研究使用FDA数据分析了glofitamab不良事件 (AE),确定细胞因子释放综合征作为关键安全信号. 发现了诸如低胺球蛋白血症等新的副作用,强调了需要持续监测和消费者教育的必要性.
科学领域:
- 药物监督 药物监督 药物监督
- 在瘤学瘤学.
- 血液学 血液学 血液学
背景情况:
- 格洛菲他马布是扩散型大B细胞淋巴瘤的有前途的治疗方法.
- 市场后监测对于全面收集安全数据至关重要.
研究的目的:
- 使用FDA不良事件报告系统数据库分析与glofitamab相关的不良事件 (AE).
- 识别重要的安全信号并调查AE模式.
主要方法:
- 用了四种不成比例分析方法来检测信号.
- 分析了AE和细胞因子释放综合征 (CRS) 的临床特征.
- 进行了敏感性分析和潜在偏差的子组调查.
主要成果:
- 从641份格洛菲他马布报告中确定了1542个AE.
- 细胞因子释放综合征 (CRS) 成为最重要的AE信号.
- 被确定为一种新的显著AE信号.
结论:
- 对于glofitamab的AE报告存在潜在的大陆差异.
- 强调教育患者早期的CRS症状和30天内的监测,特别是2.5mg的glofitamab.
- 强调了对新发现的有害事物如低血糖球蛋白血症的警的重要性.
更多相关视频
05:45Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
Published on: October 10, 2025
04:36Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
Published on: October 17, 2025
相关概念视频
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Therapeutic Drug Monitoring: Affecting Factors
Drug Regulation
Therapeutic Drug Monitoring: Overview and Classification
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...